erbb 3 receptor

Summary

Summary: A cell surface protein-tyrosine kinase receptor that is specific for NEUREGULINS. It has extensive homology to and can heterodimerize with the EGF Receptor (RECEPTOR, EPIDERMAL GROWTH FACTOR) and the erbB-2 receptor (RECEPTOR, ERBB-2). Overexpression of the erbB-3 receptor is associated with tumorigenesis.

Top Publications

  1. pmc The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
    Thomas Holbro
    Friedrich Miescher Institute, P O Box 2543, 4002 Basel, Switzerland
    Proc Natl Acad Sci U S A 100:8933-8. 2003
  2. pmc Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
    Natalia V Sergina
    Department of Medicine, University of California, San Francisco 94143, USA
    Nature 445:437-41. 2007
  3. ncbi Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
    Cancer Cell 2:127-37. 2002
  4. ncbi The deaf and the dumb: the biology of ErbB-2 and ErbB-3
    Ami Citri
    Department of Biological Regulation, The Weizmann Institute of Science, 76100, Rehovot, Israel
    Exp Cell Res 284:54-65. 2003
  5. pmc Targeting HER proteins in cancer therapy and the role of the non-target HER3
    A C Hsieh
    Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
    Br J Cancer 97:453-7. 2007
  6. ncbi Prognostic value of ERBB family mRNA expression in breast carcinomas
    Ivan Bieche
    Laboratoire d Oncogénétique INSERM E0017, Centre Rene Huguenin, St Cloud, France
    Int J Cancer 106:758-65. 2003
  7. pmc The ERBB3 receptor in cancer and cancer gene therapy
    G Sithanandam
    SAIC Frederick, MD 21702, USA
    Cancer Gene Ther 15:413-48. 2008
  8. ncbi A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy
    Si Tuen Lee-Hoeflich
    Department of Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Cancer Res 68:5878-87. 2008
  9. pmc Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
    Andrea Sassen
    Institute of Pathology, University of Regensburg, Franz Josef Strauss Allee 11, 93053 Regensburg, Germany
    Breast Cancer Res 10:R2. 2008
  10. ncbi Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients
    Teemu T Junttila
    MediCity Research Laboratories, and Department of Medical Biochemistry and Molecular Biology, Turku Graduate School of Biomedical Sciences, University of Turku, FIN 20520 Turku
    Clin Cancer Res 9:5346-57. 2003

Detail Information

Publications207 found, 100 shown here

  1. pmc The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
    Thomas Holbro
    Friedrich Miescher Institute, P O Box 2543, 4002 Basel, Switzerland
    Proc Natl Acad Sci U S A 100:8933-8. 2003
    ..Furthermore, we identify ErbB3's role, which is to couple active ErbB2 to the phosphatidylinositol 3-kinase/protein kinase B pathway. Thus, the ErbB2/ErbB3 dimer functions as an oncogenic unit to drive breast tumor cell proliferation...
  2. pmc Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
    Natalia V Sergina
    Department of Medicine, University of California, San Francisco 94143, USA
    Nature 445:437-41. 2007
    ..The biologic marker with which to assess the efficacy of HER TKIs should be the transphosphorylation of HER3 rather than autophosphorylation...
  3. ncbi Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    David B Agus
    Cedars Sinai Prostate Cancer Center, Los Angeles, California 90048, USA
    Cancer Cell 2:127-37. 2002
    ..We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment...
  4. ncbi The deaf and the dumb: the biology of ErbB-2 and ErbB-3
    Ami Citri
    Department of Biological Regulation, The Weizmann Institute of Science, 76100, Rehovot, Israel
    Exp Cell Res 284:54-65. 2003
    ..This review highlights recent structural insights into the mechanism of ligand-induced heterodimer formation, and concentrates on signaling pathways employed by ErbB-2 and ErbB-3 in normal and in malignant cells...
  5. pmc Targeting HER proteins in cancer therapy and the role of the non-target HER3
    A C Hsieh
    Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
    Br J Cancer 97:453-7. 2007
    ..This review presents the current evidence highlighting the role of HER3 in tumorigenesis and its role in mediating resistance to inhibitors of EGFR and HER2...
  6. ncbi Prognostic value of ERBB family mRNA expression in breast carcinomas
    Ivan Bieche
    Laboratoire d Oncogénétique INSERM E0017, Centre Rene Huguenin, St Cloud, France
    Int J Cancer 106:758-65. 2003
    ....
  7. pmc The ERBB3 receptor in cancer and cancer gene therapy
    G Sithanandam
    SAIC Frederick, MD 21702, USA
    Cancer Gene Ther 15:413-48. 2008
    ..Several approaches for targeting ERBB3 in cancers have been tested or proposed. Small inhibitory RNA (siRNA) to ERBB3 or AKT is showing promise as a therapeutic approach to treatment of lung adenocarcinoma...
  8. ncbi A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy
    Si Tuen Lee-Hoeflich
    Department of Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Cancer Res 68:5878-87. 2008
    ....
  9. pmc Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
    Andrea Sassen
    Institute of Pathology, University of Regensburg, Franz Josef Strauss Allee 11, 93053 Regensburg, Germany
    Breast Cancer Res 10:R2. 2008
    ..However, the clinical outcome with regard to total HER receptor state remains largely unknown...
  10. ncbi Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients
    Teemu T Junttila
    MediCity Research Laboratories, and Department of Medical Biochemistry and Molecular Biology, Turku Graduate School of Biomedical Sciences, University of Turku, FIN 20520 Turku
    Clin Cancer Res 9:5346-57. 2003
    ..The purpose of this research was to quantitatively analyze tumor-specific overexpression of all ErbB receptors and ErbB4 isoforms in transitional cell carcinoma (TCC) of the bladder...
  11. pmc Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
    Marta Guix
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6307, USA
    J Clin Invest 118:2609-19. 2008
    ..Moreover, combined therapeutic inhibition of EGFR and IGFIR may abrogate this acquired mechanism of drug resistance and is thus worthy of prospective clinical investigation...
  12. ncbi Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration
    S L Carroll
    Division of Neuropathology, Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Neurosci 17:1642-59. 1997
    ....
  13. pmc c-erbB-3: a nuclear protein in mammary epithelial cells
    Martin Offterdinger
    Signaling Networks Program, Division of Oncology, Department of Internal Medicine I, University of Vienna, A 1097 Vienna, Austria
    J Cell Biol 157:929-39. 2002
    ....
  14. ncbi HER3 is a determinant for poor prognosis in melanoma
    Markus Reschke
    Department of Molecular Biology, Max Planck Institute of Biochemistry, Munich, Germany
    Clin Cancer Res 14:5188-97. 2008
    ..However, the relevance of HER3 with regard to its prognostic significance and function in primary melanoma and metastases remains largely elusive...
  15. ncbi Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines
    A deFazio
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Sydney, Australia
    Int J Cancer 87:487-98. 2000
    ....
  16. ncbi Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
    Bin Bing S Zhou
    Drug Discovery, Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Building 400, Wilmington, Delaware 19880, USA
    Cancer Cell 10:39-50. 2006
    ..These results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacological intervention, either alone or in combination with other drugs...
  17. pmc Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin
    J Y Yoo
    Molecular and Cellular Biology Program, University of Maryland, Baltimore 21201, USA
    Br J Cancer 82:683-90. 2000
    ..Ebp1 translocated from the cytoplasm into the nucleus following heregulin stimulation. These findings suggest that Ebp1 may be a downstream member of an ErbB-3-regulated signal transduction pathway...
  18. ncbi High expression of HER3 is associated with a decreased survival in gastric cancer
    Mikiko Hayashi
    Department of Surgical Oncology, Tokyo Medical and Dental University, Tokyo, Japan
    Clin Cancer Res 14:7843-9. 2008
    ..This study investigated the positive correlation between HER1 and HER4 expression and the prognosis of patients with gastric cancers...
  19. ncbi ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases
    M A Olayioye
    Friedrich Miescher Institute, P O Box 2543, CH 4002 Basel, Switzerland
    J Biol Chem 274:17209-18. 1999
    ..Taken together, the experiments establish two independent roles for Src kinases: (i) key molecules in ErbB receptor-mediated Stat signaling and (ii) potential upstream regulators of Jak kinases...
  20. ncbi Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer
    Caroline J Witton
    University Department of Surgery, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
    J Pathol 200:290-7. 2003
    ..The development of HER-targeted agents (eg Herceptin, Iressa), and agents targeted at the downstream signalling pathways, therefore provides new possibilities in the treatment of breast cancer...
  21. ncbi Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth
    Christopher W Gregory
    Department of Pathology and Laboratory Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Clin Cancer Res 11:1704-12. 2005
    ..In these "androgen-independent" tumors, alternative means of AR activation have been invoked, including regulation by growth factors and their receptors in prostate cancer recurrence...
  22. pmc Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study
    A K Koutras
    Division of Oncology, Department of Medicine, University Hospital of Patras, Rion, Greece
    Br J Cancer 99:1775-85. 2008
    ..However, HER2 mRNA expression did not predict clinical benefit from paclitaxel. Kinetic RT-PCR represents an alternative method for evaluating the expression of HER family members in FFPE breast carcinomas...
  23. ncbi The erbB3 gene product is a receptor for heregulin
    K L Carraway
    Department of Cell Biology, Harvard Medical School, Boston, Massachusetts
    J Biol Chem 269:14303-6. 1994
    ..We conclude that ErbB3 is a receptor for HRG and is capable of mediating HRG-stimulated tyrosine phosphorylation of itself and p185erbB2/neu in cells that express both receptors...
  24. ncbi EGFR family: structure physiology signalling and therapeutic targets
    Antony W Burgess
    Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia
    Growth Factors 26:263-74. 2008
    ..EGFR and erbB2 are frequently activated, over expressed or mutated in many common cancers and the antagonists and/or inhibitors of EGFR and/or erbB2 signalling have already been shown to have therapeutic benefits for cancer patients...
  25. ncbi Severe neuropathies in mice with targeted mutations in the ErbB3 receptor
    D Riethmacher
    Department of Medical Genetics, Max Delbrueck Center for Molecular Medicine, Berlin, Germany
    Nature 389:725-30. 1997
    ..Our results indicate that sensory and motor neurons require factors for their survival that are provided by developing Schwann cells...
  26. pmc The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells
    Yuexing Zhang
    Greenebaum Cancer Center and Departments of Pathology and Pharmacology, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 102:9890-5. 2005
    ..These findings suggest that Ebp1 is a previously unrecognized therapeutic target for treatment of hormone refractory prostate cancer...
  27. ncbi Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3
    R J Fiddes
    Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Sydney, New South Wales 2010, Australia
    J Biol Chem 273:7717-24. 1998
    ..These studies therefore identify Grb7 as an in vivo target of erbB3 and erbB4 and provide an underlying mechanism for the ability of erbB3 to recruit Grb7 and not Grb2, a property unique among erbB receptors...
  28. pmc Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
    D M Abd El-Rehim
    Department of Histopathology, The Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, Hucknall Road, Nottingham NG5 1PB, UK
    Br J Cancer 91:1532-42. 2004
    ..These data imply that the combined profile expression patterns of the four receptor family members together provide more accurate information on the tumour behaviour than studying the expression of each receptor individually...
  29. ncbi Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines
    T J Lessor
    Molecular and Cellular Biology Program, University of Maryland, Baltimore, Maryland 21201, USA
    J Cell Physiol 183:321-9. 2000
    ..These data demonstrate that ectopic expression of the ErbB-3 binding protein Ebp1 inhibits proliferation and induces differentiation of ErbB-2, ErbB-3-expressing human breast carcinoma cell lines...
  30. pmc Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
    Panteleimon Kountourakis
    Second Department of Internal Medicine Propaedeutic, Athens University Medical School, Attikon University Hospital, Athens, Greece
    BMC Cancer 6:46. 2006
    ..In this study we sought to determine the pattern and the prognostic significance of HER-3 and HER-4 in colorectal adenocarcinoma...
  31. pmc Bivalence of EGF-like ligands drives the ErbB signaling network
    E Tzahar
    Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel
    EMBO J 16:4938-50. 1997
    ..Thus, ligand bivalence enables signal diversification through selective recruitment of homo- and heterodimers of ErbB receptors, and it may explain oncogenicity of erbB-2/HER2...
  32. ncbi ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells
    Judit Anido
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona 08035, Spain
    Clin Cancer Res 9:1274-83. 2003
    ..Our aim was to explore the effects of ZD1839 in breast cancer cell lines expressing different levels of EGFR and the closely related HER2 receptor...
  33. pmc Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
    Iain R Hutcheson
    Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK
    Breast Cancer Res 9:R50. 2007
    ..In the present study we have examined whether HRG signalling can circumvent EGFR blockade in an EGFR-positive tamoxifen-resistant MCF-7 (Tam-R) breast cancer cell line...
  34. ncbi Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue
    T Ekberg
    Otorhinolaryngology and Head and Neck Surgery, Akademiska sjukhuset, Uppsala University, SE 751 85 Uppsala, Sweden
    Int J Oncol 26:1177-85. 2005
    ..g. using radiolabelled antibodies or ligands, and EGFR seemed suitable as target since the expression was high, membrane associated and similar in the primary tumours and the corresponding metastases...
  35. pmc C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators
    A Travis
    Department of Histopathology, City Hospital, Nottingham, UK
    Br J Cancer 74:229-33. 1996
    ..It seems, however, unlikely that c-erbB-3 protein expression will emerge as a powerful enough prognostic factor to be of value in clinical practice...
  36. ncbi Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast
    Nicola L P Barnes
    Department of Academic Surgery, South Manchester University Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, United Kingdom
    Clin Cancer Res 11:2163-8. 2005
    ..Potentially, HER4 expression may identify women who could avoid radiotherapy after breast-conserving surgery for DCIS...
  37. pmc Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3
    C Wallasch
    Department of Molecular Biology, Max Planck Institut fur Biochemie, Martinsried, Germany
    EMBO J 14:4267-75. 1995
    ....
  38. ncbi Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription
    Yuexing Zhang
    Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Biol Chem 279:26126-33. 2004
    ..Our findings suggest that Ebp1, by linking HRG activation of membrane receptors to E2F gene activity, may be a downstream modulator of the effects of HRG on cell cycle progression...
  39. pmc Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer
    P M Siegel
    Institute for Molecular Biology and Biotechnology, McMaster University, Hamilton, Ontario, Canada L8S 4K1
    EMBO J 18:2149-64. 1999
    ....
  40. ncbi The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
    Thomas P J Garrett
    Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, 3050, Parkville, Victoria, Australia
    Mol Cell 11:495-505. 2003
    ..Together, the data suggest a model in which ErbB2 is already in the activated conformation and ready to interact with other ligand-activated ErbB receptors...
  41. pmc The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system
    S Britsch
    Department of Medical Genetics, Max Delbruck Center MDC for Molecular Medicine, 13122 Berlin, Germany
    Genes Dev 12:1825-36. 1998
    ..Together with previous observations, these findings establish the neuregulin signaling system as a key regulator in the development of neural crest cells...
  42. ncbi The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases
    Melanie B Laederich
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    J Biol Chem 279:47050-6. 2004
    ....
  43. ncbi Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells
    Kaisa Erjala
    Department of Otorhinolaryngology Head and Neck Surgery, Turku University Central Hospital, Finland
    Clin Cancer Res 12:4103-11. 2006
    ..Research on non-small cell lung cancer has elucidated factors that may predict response to gefitinib. Less is known about molecular markers that may predict response to gefitinib in HNSCC patients...
  44. pmc Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue
    Karl Ludwig Schaefer
    Institute of Pathology, Heinrich Heine University, Dusseldorf, Germany
    Neoplasia 8:613-22. 2006
    ....
  45. ncbi mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen
    Francoise Revillion
    Laboratoire d Oncologie Moléculaire Humaine, Centre Oscar Lambret, 3 Rue Frederic Combemale, BP 309, 59020 Lille, France
    Anticancer Res 23:1455-60. 2003
    ..In the present paper, we simultaneously quantified, for the first time, the mRNA expression of these four receptors in response to estradiol and 4-hydroxy-tamoxifen in the prototypical ER-positive human breast cancer cell line MCF-7...
  46. ncbi Analysis of the expression pattern of Ebp1, an ErbB-3-binding protein
    X Xia
    Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201, USA
    Biochem Biophys Res Commun 289:240-4. 2001
    ..5 kDa. The molecular mass of endogenous Ebp1 protein derived from mouse liver and brain was determined by mass spectrometry and the data confirm that translation of endogenous Ebp1 in tissues is initiated from the second in-frame ATG...
  47. ncbi Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
    M Alimandi
    Laboratory of Cellular and Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncogene 10:1813-21. 1995
    ....
  48. ncbi Multiple essential functions of neuregulin in development
    D Meyer
    Nature 378:386-90. 1995
    ..All cell types affected by the mutation express either erbB3 or erbB4, indicating that either of these tyrosine kinase receptors can be a component in recognition and transmission of essential neuregulin signals...
  49. ncbi A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4
    H Lee
    Tumor Biology Program, Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Res 61:4467-73. 2001
    ....
  50. pmc Expression of c-erbB3 protein in primary breast carcinomas
    R Naidu
    Department of Genetics and Cellular Biology, University of Malaya, Kuala Lumpur, Malaysia
    Br J Cancer 78:1385-90. 1998
    ....
  51. ncbi Neuregulins are concentrated at nerve-muscle synapses and activate ACh-receptor gene expression
    S A Jo
    Center for Blood Research, Harvard Medical School, Boston, Massachusetts 02115
    Nature 373:158-61. 1995
    ....
  52. pmc Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    J Clin Invest 116:2695-706. 2006
    ....
  53. pmc Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
    Thomas Frogne
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
    Breast Cancer Res Treat 114:263-75. 2009
    ..Our data support that a concerted action against EGFR, ErbB2 and ErbB3 may be required to obtain complete growth suppression of fulvestrant resistant cells...
  54. pmc Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling
    Sian M Tovey
    Endocrine Cancer Group, Division of Cancer Sciences and Molecular Biology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
    Breast Cancer Res 6:R246-51. 2004
    ..In this study, bromodeoxyuridine (BrdU)-derived proliferation indices are correlated with clinical outcome and HER1-4 status for further clarification of the differing roles for the HER family at a biological level...
  55. ncbi The ErbB receptors and their role in cancer progression
    Thomas Holbro
    Friedrich Miescher Institute, PO Box 2543, 4002, Basel, Switzerland
    Exp Cell Res 284:99-110. 2003
    ..e., ErbB1 cooperates with other classes of receptors, and the ligand-less ErbB2 functions as a heterodimer with other ErbBs...
  56. ncbi Isoform-specific expression and function of neuregulin
    D Meyer
    Max Delbruck Center for Molecular Medicine, Department of Medical Genetics, Berlin, Germany
    Development 124:3575-86. 1997
    ..The complexity of neuregulin functions in development is therefore due to independent roles played by distinct isoforms...
  57. ncbi EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival
    Zhenhe Suo
    Department of Pathology, The Norwegian Radium Hospital and Institute for Cancer Research, University of Oslo, Oslo, Norway
    J Pathol 196:17-25. 2002
    ..However, c-erbB-4 antagonizes the c-erbB-2 effect on clinical course in breast carcinomas. To achieve best results with immunotherapy against the c-erbB-2 receptor, clarifying the status of c-erbB-4 expression may be of significance...
  58. pmc Phosphotyrosine interactome of the ErbB-receptor kinase family
    Waltraud X Schulze
    Department of Biochemistry and Molecular Biology, Center for Experimental Bioinformatics, University of Southern Denmark, Odense, Denmark
    Mol Syst Biol 1:2005.0008. 2005
    ..Our results demonstrate that system-wide mapping of peptide-protein interactions sites is possible, and suggest shared and unique roles of ErbB-receptor family members in downstream signaling...
  59. pmc The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies
    Anne W Hamburger
    Greenebaum Cancer Center and Department of Pathology, University of Maryland, Baltimore, BRB 9 029, 655 W Baltimore Street, Baltimore, MD 21201, USA
    J Mammary Gland Biol Neoplasia 13:225-33. 2008
    ..These studies point to the importance of the evaluation of protein levels and functional activity of ErbB3 and its binding proteins in breast cancer prognosis and prediction of clinical response to treatment...
  60. ncbi Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells
    Bolin Liu
    Department of Pathology and College of Medicine, University of Colorado at Denver and Health Sciences Center UCDHSC, Aurora, CO, USA
    Int J Cancer 120:1874-82. 2007
    ..Furthermore, erbB3 also contributes to erbB2-mediated tamoxifen resistance and therefore may be a clinically relevant therapeutic target in addition to erbB2...
  61. ncbi An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)
    Laura Ferrer-Soler
    Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Int J Mol Med 20:3-10. 2007
    ....
  62. ncbi c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function
    R C Ishizawar
    Department of Microbiology and Cancer Center, University of Virginia Health System, Charlottesville, VA 22908, USA
    Oncogene 26:3503-10. 2007
    ....
  63. pmc Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response
    Harish Shankaran
    Pacific Northwest National Laboratory, Richland, WA, USA
    Biophys J 90:3993-4009. 2006
    ..Results indicate that coexpression of EGFR with HER2 and HER3 at low to moderate levels may enable cells to match the response of a high HER2 expresser...
  64. ncbi ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
    David F Stern
    Department of Pathology, Yale University School of Medicine, P O Box 208023, New Haven, CT 06520 8023, USA
    J Mammary Gland Biol Neoplasia 13:215-23. 2008
    ....
  65. ncbi Role of neuregulin-1 beta in the developing lung
    Christiane E L Dammann
    Department of Pediatrics, Division of Newborn Medicine, Floating Hospital for Children at Tufts New England Medical Center, 750 Washington Street, Boston, MA, USA
    Am J Respir Crit Care Med 167:1711-6. 2003
    ..Thus, neuregulin-1 beta may control fetal lung maturation through mesenchymal-epithelial interactions in a paracrine mechanism similar to that described for the developing heart, brain, and mammary systems...
  66. ncbi Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
    Y Qiu
    Department of Molecular Biology and Microbiology, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, USA
    Nature 393:83-5. 1998
    ..Thus ErbB2 is a critical component of IL-6 signalling through the MAP kinase pathway. These data show how a cytokine receptor can diversify its signalling pathways by engaging with a growth-factor receptor kinase...
  67. ncbi ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib
    Andrey Frolov
    Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Cancer Biol Ther 6:548-54. 2007
    ..Pancreatic cancer expression of ErbB3 may be useful for EGFR-targeted therapy patient selection...
  68. ncbi Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells
    Jae In Jung
    Department of Food Science and Nutrition and Silver Biotechnology Research Center, Hallym University, Chuncheon, Korea
    Biofactors 28:159-68. 2006
    ..These results indicate that ISL inhibits the proliferation of prostate cancer cells, at least in part, via the inhibition of ErbB3 signaling and the PI3K/Akt pathway...
  69. ncbi Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor
    N J Hellyer
    Department of Pharmacology, The University of Iowa, College of Medicine, Iowa City, Iowa 52242 1109, USA
    J Biol Chem 276:42153-61. 2001
    ..Recruitment of PI 3-kinase to ErbB3 was required for both activities, and it appeared that ErbB2 activation alone was not sufficient to activate PI 3-kinase signaling in these cells...
  70. ncbi Neuregulin-1 enhances motility and migration of human astrocytic glioma cells
    Patricia A Ritch
    Department of Neurobiology and Civitan International Research Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Biol Chem 278:20971-8. 2003
    ..Taken together these data suggest that neuregulin-1 plays an important modulatory role in glioma cell invasion...
  71. pmc ErbB expression: the mouse inner ear and maturation of the mitogenic response to heregulin
    Clifford R Hume
    Department of Otolaryngology Head and Neck Surgery, Virginia Merrill Bloedel Hearing Research Center, University of Washington, Seattle, WA 98195 7923, USA
    J Assoc Res Otolaryngol 4:422-43. 2003
    ..The distribution of erbBs in the neonatal and adult mouse ear is consistent with the EGF receptor/ligand family regulating diverse cellular processes in the inner ear, including cell proliferation and differentiation...
  72. pmc Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors
    Thomas Frogne
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, Copenhagen, Denmark
    Breast Cancer Res 11:R11. 2009
    ..In the present study we examined the importance of active HER signaling in breast tumor biopsies and paired metastases, by evaluating the expression of phosphorylated HER1, HER2, HER3, Erk, Akt and the total level of HER4 and HER2...
  73. ncbi Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours
    G Lammering
    Department of Radiation Oncology, University Hospital Dusseldorf, Germany
    Int J Radiat Biol 79:561-8. 2003
    ....
  74. ncbi Ebp1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation
    X Xia
    Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201, USA
    J Cell Physiol 187:209-17. 2001
    ..Ebp1 bound E2F1 indirectly via Rb in lysates of MCF-7 cells. The interaction of Ebp1 with Rb may prove to be an important mechanism of Ebp1 induced changes in cell proliferation and differentiation...
  75. ncbi Expression and nuclear localization of ErbB3 in prostate cancer
    Ismael Herve Koumakpayi
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Quebec, Canada
    Clin Cancer Res 12:2730-7. 2006
    ..The aim of this study was to analyze the expression and localization of ErbB3 in prostate tissues and prostate cancer cell lines...
  76. ncbi ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice
    S L Erickson
    Department of Molecular Biology, Genetech Inc, South San Francisco, California 94080, USA
    Development 124:4999-5011. 1997
    ..Numerous organs, including the stomach and pancreas also exhibited anomalous development...
  77. pmc Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients
    A A Memon
    Department of Clinical Biochemistry, AKH University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark
    Br J Cancer 91:2034-41. 2004
    ..While it is well established that an increased signalling through HER1 and HER2 is related to a poor prognosis, our data suggest that signalling through HER3 and HER4 is related to a favourable outcome in bladder cancer patients...
  78. ncbi Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival
    Sam M Wiseman
    Genetic Pathology Evaluation Center at the Prostate Research Center of Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer 103:1770-7. 2005
    ..The objective of the current study was to determine the frequency and the possible prognostic effect of coexpression of HER-1, HER-2, HER-3, and HER-4 by breast carcinoma...
  79. pmc Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer
    Sue Hwa Lin
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:3729-36. 2008
    ..We aimed to understand clinical implications of sErbB3 by establishing an ELISA to detect sErbB3 levels in bone marrow and plasma samples...
  80. pmc Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling
    Linlin Wang
    Division of Hematology, Department of Medicine, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, 98195, USA
    Blood 110:4111-9. 2007
    ..These studies identify previously unappreciated RTKs that support hESC proliferation and self-renewal, and provide a rationally designed medium for the growth and maintenance of pluripotent hESCs...
  81. ncbi Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer
    Ismael H Koumakpayi
    Centre de recherche du Centre Hospitalier de l Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada
    BJU Int 100:303-9. 2007
    ....
  82. pmc The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins
    B L Smith
    Cell Signaling Technology, 166B Cummings Center, Beverly, MA 01915, USA
    Br J Cancer 91:1190-4. 2004
    ....
  83. ncbi Mapping nucleolar and spliceosome localization sequences of neuregulin1-beta3
    Matthew Golding
    Receptor Biology Laboratory, Imperial Cancer Research Fund Laboratories, Hammersmith Hospital, London, UK
    Exp Cell Res 299:110-8. 2004
    ....
  84. ncbi Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow
    Funda Vakar-Lopez
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Pathol 203:688-95. 2004
    ..These observations indicate that MDA-BF-1 is up-regulated in metastatic PCa and raise the interesting possibility that MDA-BF-1 may play a role in the metastasis and progression of PCa, particularly in bone...
  85. ncbi Association of type 1 diabetes with two Loci on 12q13 and 16p13 and the influence coexisting thyroid autoimmunity in Japanese
    Takuya Awata
    Division of Endocrinology and Diabetes, Department of Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma gun, Saitama 350 0495, Japan
    J Clin Endocrinol Metab 94:231-5. 2009
    ..Recent genome-wide association studies have identified several novel type 1 diabetes (T1D) loci in white populations...
  86. pmc Embryonic requirements for ErbB signaling in neural crest development and adult pigment pattern formation
    Erine H Budi
    Department of Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98195 1800, USA
    Development 135:2603-14. 2008
    ..These data identify a very early, embryonic, requirement for erbb3b in the development of much later metamorphic melanophores, and suggest complex modes by which ErbB signals promote adult pigment pattern development...
  87. ncbi ErbB-3 predicts survival in ovarian cancer
    Berno Tanner
    Department of Gynecology and Obstetrics, University of Mainz, Mainz, Germany
    J Clin Oncol 24:4317-23. 2006
    ..Here, we studied a possible association between HER3 expression and prognosis in patients with ovarian cancer...
  88. ncbi A dimerization hierarchy in the transmembrane domains of the HER receptor family
    Jean Pierre Duneau
    Unité Propre de Recherche 9027 Laboratoire d Ingénierie des Systèmes Macromoléculaires, Institut de Biologie Structurale et Microbiologie, Centre National de la Recherche Scientifique, Marseille, France
    Biochemistry 46:2010-9. 2007
    ..The correlation we observe between transmembrane domain and whole receptor interaction hierarchies opens a new perspective, suggesting a role for transmembrane receptor domains in the modulation of receptor signaling...
  89. ncbi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Science 316:1039-43. 2007
    ..Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well...
  90. ncbi Gene copy numbers of HER family in breast cancer
    Anna Zaczek
    Department of Oncology and Radiotherapy, Medical University of Gdansk, Debinki 7, 80 211 Gdansk, Poland
    J Cancer Res Clin Oncol 134:271-9. 2008
    ..The aim of the study was to analyze the occurrence of abnormal gene copy numbers of all HER oncogenes and to correlate these alterations to other clinicopathological variables in a consecutive series of 225 breast cancer patients...
  91. ncbi Mapping ErbB receptors on breast cancer cell membranes during signal transduction
    Shujie Yang
    Department of Pathology and Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, USA
    J Cell Sci 120:2763-73. 2007
    ..These data suggest that the distinct topography of receptors and their docking partners modulates signaling activities...
  92. pmc Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells
    Aeree Kim
    Department of Pathology and College of Medicine, Oklahoma University Health Sciences Center OUHSC, Oklahoma City, OK, USA
    Breast Cancer Res 7:R708-18. 2005
    ..We hypothesized that physical and functional interactions between the wt rat neu/ErbB2 transgene and mouse ErbB3-encoded proteins could occur, activating downstream signaling and promoting mammary oncogenesis...
  93. ncbi HER3 and mutant EGFR meet MET
    Carlos L Arteaga
    Nat Med 13:675-7. 2007
  94. pmc ErbB3 is required for ductal morphogenesis in the mouse mammary gland
    Amy J Jackson-Fisher
    Department of Pathology, Yale School of Medicine, New Haven, CT 06520 8023, USA
    Breast Cancer Res 10:R96. 2008
    ..Understanding ErbB3 functions in the normal mammary gland will help to explain its role in cancer etiology and as a modulator of signaling responses to the mammary oncogene ERBB2...
  95. ncbi Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers
    Wenle Xia
    Departments of Oncology Biology, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    Cancer Res 66:1640-7. 2006
    ..These findings shed new light on the mechanism by which ErbB2 overexpression protects against apoptotic stimuli in breast cancer and identifies therapeutic interventions to improve clinical outcomes in these aggressive tumors...
  96. pmc The transcription factor Sox10 is a key regulator of peripheral glial development
    S Britsch
    Max Delbruck Center for Molecular Medicine, D 13122 Berlin, Germany
    Genes Dev 15:66-78. 2001
    ..Haploinsufficiency of Sox10 can thus cause pigmentation and megacolon defects, which are also observed in Sox10(Dom)/+ mice and in patients with Waardenburg-Hirschsprung disease caused by heterozygous SOX10 mutations...
  97. ncbi Neuregulin, a factor with many functions in the life of a schwann cell
    A N Garratt
    Max Delbrück Centrum for Molecular Medicine, Berlin, Germany
    Bioessays 22:987-96. 2000
    ..They serve as a model to study glia-nerve interactions in vivo and indicate that Schwann cells provide important neurotrophic signals, and also cues that regulate perineurium development and nerve fasciculation...
  98. ncbi Expression of heregulin and ErbB/Her receptors in adult chinchilla cochlear and vestibular sensory epithelium
    Mei Zhang
    Hearing Research Lab, 215 Parker Hall, University at Buffalo, Buffalo, NY 14214, USA
    Hear Res 169:56-68. 2002
    ..These results suggest that heregulin acting through ErbB receptors and various receptor complexes may play an important role in cell proliferation and survival in the cochlea and vestibular system...
  99. ncbi Neuregulin induces the rapid association of focal adhesion kinase with the erbB2-erbB3 receptor complex in schwann cells
    T Vartanian
    Department of Neurology, Harvard Medical School and Beth Israel Deaconess Hospitals, Boston, Massachusetts
    Biochem Biophys Res Commun 271:414-7. 2000
    ....
  100. ncbi Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2
    Peter Nagy
    Department of Biophysics and Cell Biology, Medical and Health Science Center, University of Debrecen, POB 39, Debrecen H 4012, Hungary
    J Cell Sci 115:4251-62. 2002
    ..We conclude that local densities of ErbB2 and ErbB3, as well as the lipid environment profoundly influence the association properties and biological function of ErbB2...
  101. ncbi Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1
    Yuexing Zhang
    Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, MD 21201, USA
    Oncogene 21:5609-18. 2002
    ..These studies suggest that Ebp1 may play a role in the function of the AR and provide a link between ErbB receptors and the AR...

Research Grants27

  1. ERBB-3 DOMAINS AND THE COOPERATION WITH ERBB-2
    Paolo Fedi; Fiscal Year: 2000
    ..Understanding the cooperation between these two receptors will be importance for evaluating the prognostic value of the expression of the erbB-2 and erbB-3 oncogenes in human cancer. ..
  2. Pilot studies to develop probes for in vivo imaging of P13K/Akt pathway activity
    Mark Moasser; Fiscal Year: 2008
    ..If successful, this modality could potentially lead to a ground-breaking predictive clinical monitoring tool. ..
  3. Adhesion signaling by a novel mitotic substrate of src
    Mark Moasser; Fiscal Year: 2009
    ..abstract_text> ..
  4. Regulation of Angiogenesis by C CAM1
    Sue Hwa Lin; Fiscal Year: 2004
    ..Achieving these aims will provide valuable information for applying CCAM1 for prostate cancer therapy and for developing C-CAM1 combination therapy. ..
  5. Bone Metastasis Factor-1 in Prostate Cancer/Bone Interaction
    Sue Hwa Lin; Fiscal Year: 2009
    ..Investigate the mechanism of MDA-BF-1-mediated osteoblast proliferation and differentiation;and Aim 3. Purify, identify, and clone the receptor for MDA-BF-1 (BF1-receptor). ..
  6. PROTEIN KINASES IN YEAST DNA CHECKPOINT PATHWAYS
    David Stern; Fiscal Year: 2009
    ..Aim 3. Molecular techniques will be used for functional analysis of NFBD1/MDC1 in the activities identified in Aim 2. ..
  7. Determinants of Resistance to Erlotinib in NSCLC
    Roman Perez Soler; Fiscal Year: 2010
    ..To confirm the predictive value of the algorithm in a group of patients with chemoresistant NSCLC selected for their high probability of achieving a response or stable disease with single agent erlotinib therapy. ..
  8. TAM Receptor Regulation of Innate Immunity
    GREG E LEMKE; Fiscal Year: 2011
    ..Together, these studies will provide basic insights into a new signaling system of critical importance to the regulation of immune responses and the development of autoimmunity. ..
  9. Regulation of auditory neuron neurite growth by activity
    Marlan Hansen; Fiscal Year: 2008
    ..The results of these studies will provide critical data on the consequences of electrical activity on SGN neurite growth and cochlear innervation. ..
  10. Potentiation of Topo Inhibitors by the HDACi, SAHA
    Pamela Munster; Fiscal Year: 2007
    ..These findings may be useful in the rational design of future clinical trials involving HDACi. [unreadable] [unreadable]..
  11. Modulation of ErbB Receptor Tyrosine Kinase Signaling
    Kermit L Carraway; Fiscal Year: 2011
    ..Specific Aim 2 examines the molecular mechanisms by which Muc4 alters receptor trafficking and localization. ..
  12. ERBB 2 ERBB 3 HETERODIMERIC RECEPTOR OF CARCINOMAS
    Yosef Yarden; Fiscal Year: 2004
    ..This model will be examined by using mutant receptors, and the recycling machinery characterized in details. The suspected cancer-inhibitory activity of drugs interfering with ErbB routing will be tested in vivo. ..
  13. HETERODIMERIZATION AND ERBB RECEPTOR SIGNALING
    KERMIT CARRAWAY; Fiscal Year: 2001
    ....
  14. UC4 AP4 Cancer Therapy Center
    Paul Bunn; Fiscal Year: 2004
    ..Chan, PI); 2) vaccine/ DNAI/ RNA therapy (R. Garcea, PI); 3) angiogenic inhibitors/ PK/ PD modeling (S.G. Eckhardt, PI); and 4) chemoprevention agents (R. Nemenoff, PI). ..
  15. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2003
    ..The results of this study will provide initial but very valuable information on the potential use of this new strategy in the treatment of bronchial premalignancy, carcinoma in situ, and endobronchial lung tumors. ..
  16. FUNCTIONAL STUDIES OF TYRO 3 FAMILY RECEPTORS
    Greg Lemke; Fiscal Year: 2004
    ..Together, these studies will reveal the basics of cell-to-cell signaling through Tyro 3, Axl, and Mer -- three receptors of genuine biological importance. ..
  17. EBP1 CONTROL OF PROSTATE CANCER CELL GROWTH
    Anne Hamburger; Fiscal Year: 2002
    ..Deletion constructs generated will be used to determine if the inhibitory effects of Ebp1 on AR-mediated transcription and cell growth are related to the ability of this protein to bind AR. ..
  18. Long-Circulating Liposomal Camptothecins CAP and EAP
    Roman Perez Soler; Fiscal Year: 2003
    ..Ultimately, we will seek formulation(s) that display optimized drug retention and in vivo and in vitro performance. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  19. Potentiation of Topo Inhibitors by HDAC Inhibitors
    Pamela Munster; Fiscal Year: 2005
    ..Finally, the utility of the topo II inhibitors could be enhanced if their efficacy could be increased without worsening toxicity, as our preclinical data appears to indicate. ..
  20. INNOVATIVE TUMOR TARGETED THERAPIES FOR LUNG CANCER
    Roman Perez Soler; Fiscal Year: 2004
    ..Four such candidates have already been identified. It is anticipated that a total of ten young clinical investigators will be mentored during a five-year period. ..
  21. Functional Genomics Tools for HER2 heterodimers and Androgen Receptor Signaling
    Anjali Jain; Fiscal Year: 2007
    ..Androgen receptor is one such protein. Our research proposes to develop methods to search for compounds that specifically block the androgen receptor in prostate cancer cells. [unreadable]..
  22. Study of GPR30: a novel estrogen receptor linked to breast cancer.
    Edward J Filardo; Fiscal Year: 2010
    ....
  23. Chemotherapy and anti-EGFR Antibody C225 in Lung Cancer
    Roman Perez Soler; Fiscal Year: 2004
    ..abstract_text> ..
  24. ERBB RECEPTOR CONTROL OF BREAST CANCER GROWTH
    Anne Hamburger; Fiscal Year: 2006
    ..An understanding of the mechanisms by which Ebp1 inhibits cell growth and induces differentiation may contribute to the design of new molecular targets for cancer therapy. ..
  25. Neuregulin-2 and the formation of neuromuscular synapses
    Mendell Rimer; Fiscal Year: 2006
    ..Results from the proposed research are expected to yield new insights into the molecular mechanisms that control neurotransmitter receptor density at the NMJ, which may bear on such control at synapses in the brain. ..
  26. NEUREGULINS AND THEIR RECEPTORS IN LUNG DEVELOPMENT
    CHRISTIANE DAMMANN; Fiscal Year: 2005
    ..This should contribute to the development of diagnostic and therapeutic strategies that reduce the burden of acute and chronic lung disease among preterm infants. ..
  27. Glial-Neuron Interactions: Genetic Studies
    Greg Lemke; Fiscal Year: 2005
    ..Together, these studies will yield fundamental new insights into the transcriptional regulation of glial-neuron interactions in the developing central and peripheral nervous systems. ..